| Patents for C07D 403 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group (62,587) |
|---|
| 06/28/2006 | CN1794985A Azabicyclo derivatives as muscarinic receptor antagonists |
| 06/28/2006 | CN1793139A Tech, Process for dimethyl violuric acid catalyzing hydrogenation reaction |
| 06/28/2006 | CN1261430C Novel benzazepines and related heterocyclic derivatives which are useful as orexin receptor antagonists |
| 06/27/2006 | US7067662 CXCR3 antagonists |
| 06/27/2006 | US7067656 Sulfamoyl compounds and agricultural and horticultural fungicides |
| 06/27/2006 | US7067655 Adenosine A2a receptor antagonists |
| 06/27/2006 | US7067622 Performing automatic synthesis by a solid phase Fmoc method with the use of a peptide synthesizer and a HATU[O-(7-azobenzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate]/DIEA(N,N-diisopropylethylamine) system |
| 06/27/2006 | US7067551 Deacetylase inhibitors |
| 06/27/2006 | US7067549 Pyrrolidone carboxamides |
| 06/27/2006 | US7067546 high yield, industrial scale crystallization of 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl) biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylic acid (Candesartan) from solution or suspension with an aprotic polar solvent, between zero and 30 degrees Celsius |
| 06/27/2006 | US7067525 Compounds useful as modulators of Melanocortin Receptors and pharmaceutical compositions comprising same |
| 06/27/2006 | US7067522 anticarcinogenic, antitumor, antiproliferative agents; focal adhesion kinase (FAK) and cyclin-dependent kinase (CDK) enzyme inhibitors |
| 06/27/2006 | US7067517 Use of compounds for decreasing activity of hormone-sensitive lipase |
| 06/27/2006 | US7067514 Pyrimidine compounds |
| 06/27/2006 | US7067513 Phenylpiperazines |
| 06/27/2006 | US7067512 Substituted 1,4-benzodiazepines and uses thereof |
| 06/27/2006 | US7067506 Compounds useful for inhibiting Chk1 |
| 06/22/2006 | WO2006066197A1 Tetrahydroisoquinoline compounds for treatment of cns disorders |
| 06/22/2006 | WO2006066079A2 Pyridazinone compounds |
| 06/22/2006 | WO2006065726A2 Process for preparing voriconazole |
| 06/22/2006 | WO2006065590A2 Pyridine and pyrimidine antiviral compositions |
| 06/22/2006 | WO2006065480A2 Tetrahydrocarbazoles as active agents for inhibiting vegf production by translational control |
| 06/22/2006 | WO2006065277A2 Heterocyclic aspartyl protease inhibitors |
| 06/22/2006 | WO2006065216A1 Novel hydantoin derivatives as metalloproteinase inhibitors |
| 06/22/2006 | WO2006064366A1 6- (1h-pyrazol-5-yl)-1, 3, 5-triazine derivatives and their use as protective agents against uv radiation |
| 06/22/2006 | WO2006064251A1 4- (4- (imidazol-4-yl) pyrimidin-2-ylamino) benzamides as cdk inhibitors |
| 06/22/2006 | WO2006064044A1 Indolinones and their use as antiproliferative agents |
| 06/22/2006 | WO2006063863A1 Biaromatic compounds that modulate ppar type receptors, process for preparing them and use thereof in cosmetic or pharmaceutical compositions |
| 06/22/2006 | WO2006063578A2 Method for production of candesartan |
| 06/22/2006 | WO2006063466A1 2-(phenyl or heterocyclic)-1h-phenantrho[9,10-d]imidazoles as mpges-1 inhibitors |
| 06/22/2006 | WO2006028904A9 Quinazolines useful as modulators of ion channels |
| 06/22/2006 | WO2006023562B1 5-[3-(4-Benzyloxyphenylthio)-fur-2-yl]-imidazolidin-2, 4-dione and analogues as inhibitors of macrophage elastase |
| 06/22/2006 | WO2006021884A3 Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors |
| 06/22/2006 | WO2006019632A3 Cell adhesion inhibitors |
| 06/22/2006 | WO2006013049A3 Benzyloxy derivatives as maob inhibitors |
| 06/22/2006 | WO2005077941A3 Candesartan cilexetil polymorphs |
| 06/22/2006 | US20060135780 Synthesis of a novel intermediate, 2-(1-trityl-1H-tetrazol-5-yl)phenylboronic acid, by combining 5-phenyl-1H-tetrazole with chlorotriphenylmethane and then reacting with a borate, both in basic solutions; a Suzuki coupling reaction with a protected imidazolephenylboronic acid will give irbesartan |
| 06/22/2006 | US20060135778 Pesticidal 5-(acylamino) pyrazole derivatives |
| 06/22/2006 | US20060135776 4-Cyanopyrazole-3-carboxamide derivatives, preparation, and application thereof |
| 06/22/2006 | US20060135771 Quinoline derivatives as nk-2 and nk-3 receptor antagonists |
| 06/22/2006 | US20060135770 PARP inhibitors |
| 06/22/2006 | US20060135769 Farnesyl transferase inhibiting 4-heterocyclyl-quinoline and quinazoline derivatives |
| 06/22/2006 | US20060135762 Preventing the deposits of amyloid protein, treating neurodegenerative disease, Alzheimer's disease and Down's Syndrome; {[carbamoyl]cycloalkyl}-N-(2-oxo-5-phenyl((S)-3H-benzo[f]1,4-diazepin-3-yl))- or (2-oxo-5-phenyl((S)-3H-benzo[f]1,4-diazepin-3-yl))-carboxamide |
| 06/22/2006 | US20060135659 Having at least one sterically hindered nitroxyl, hydroxylamine or hydrocarbyloxyamine moiety and at least one conventional organohalogen or organophosphorus flame retardant moiety: 1-cyclohexyloxy-2,2,6,6-tetramethyl-4-piperidinyl diphenyl phosphate; fireproofing organic polymer substrates |
| 06/22/2006 | US20060135594 Dihydropyrrole derivatives; 3-{(2S)-4-(2,5-difluorophenyl)-1-[(dimethylamino)carbonyl]-2,5-dihydro- 1H-pyrrol-2-yl}phenyl dihydrogen phosphate; anticarcinogenic agents; cellular proliferative diseases; specificity; side effect reduction |
| 06/22/2006 | US20060135593 N-acyl nitrogen heterocyles as ligands of peroxisome proliferator-activated receptors |
| 06/22/2006 | US20060135592 Indolinones and their use as antiproliferative agents |
| 06/22/2006 | US20060135589 1h-Indazole-3-carboxamide compounds as cyclin dependent kinase (cdk) inhibitors |
| 06/22/2006 | US20060135565 Crystalline form of rabeprazole sodium |
| 06/22/2006 | US20060135559 Novel imidazoline compounds |
| 06/22/2006 | US20060135554 Novel compounds |
| 06/22/2006 | US20060135553 Imidazole derivatives |
| 06/22/2006 | US20060135544 A Suzuki coupling reaction of 2-butyl-3-(4-bromobenzyl)-1,3-diazaspiro[4.4]non-1-ene-4-one and 2-((1-trityl-1H-tetrazol-5-yl))phenylboronic acid in a basic solvent system with a palladium or nickel complex catalyst |
| 06/22/2006 | US20060135543 N4-(1,4-Benzoxazin-6-yl)-5-fluoro-N2-[3-(N-methylamino)carbonylmethyleneoxyphenyl]-2,4-pyrimidinediamine or a salt, hydrate, solvate and/or N-oxide; inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators; Syk kinase inhibitors |
| 06/22/2006 | US20060135541 (3-((Quinazolin-4-yl) amino)-1h-pyrazol-1-yl)acetamide derivatives and related compounds as aurora kinase inhibitors for the treatment of proliferative diseases such as cancer |
| 06/22/2006 | US20060135530 Such as (2E)-3-[3-(aminomethyl)-2-isobutyl-4-(4-methylphenyl)quinolin-6-yl]acrylamide; dipeptidyl peptidase IV inhibitors; diabetes, obesity, glucose intolerance |
| 06/22/2006 | US20060135528 For treatment and/or prevention of diseases which are associated with the modulation of H3 receptors; treatment of obesity; N-[2-(4-ethyl-piperazin-1-yl)-pyridin-4-yl]-propionamide, 1-[2-(4-ethyl-piperazin-1-yl)-pyridin-4-yl]-3-propyl-urea |
| 06/22/2006 | US20060135524 delta-opioid receptor agonists as analgesics having reduced side effects and antagonists as immunosuppressants, antiinflammatory agents, neurological, psychiatric , urological and reproductive conditions; e.g. 10-(8-Methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide |
| 06/22/2006 | US20060135523 2-substituted 5,6-diaryl-pyrazine derivatives as cb1 modulator |
| 06/22/2006 | US20060135519 5-aryltetrazole compounds and compositions thereof |
| 06/22/2006 | US20060135511 Benzodiazepine cgrp receptor antagonists |
| 06/22/2006 | US20060135487 Piperazine derivatives and their use as anti-inflammatory agents |
| 06/22/2006 | US20060135367 2,5 -Difluoro-N-isobutyl-N-(8-propyl-[1,2,4]triazolo,[1,5-c]pyrimidin-7-ylmethyl)-benzamide; gamma aminobutyric acid receptor (GABAR) agonist/antagonist; anxiolitic, antidepressant; sleep disorder, attention deficit disorder, schizophrenia or Alzheimer's dementia |
| 06/22/2006 | US20060134764 Gene cluster involved in safracin biosynthesis and its uses for genetic engineering |
| 06/22/2006 | DE102004061593A1 Substituierte N-heterocyclische Verbindungen und ihre therapeutische Verwendung Substituted N-heterocyclic compounds and their therapeutic use |
| 06/22/2006 | DE102004061009A1 Substituierte 1,2,4-Triazin-5(2H)-one Substituted 1,2,4-triazine-5 (2H) -ones |
| 06/22/2006 | DE102004061008A1 3-Arylalkyl- und 3-Heteroarylalkyl-substituierte 1,2,4-Triazin-5(2H)-one 3-arylalkyl and heteroarylalkyl 3-substituted-1,2,4-triazine-5 (2H) -ones |
| 06/22/2006 | DE102004061006A1 3-Benzylthio-1,2,4-triazin-5(2H)-one 3-benzylthio-1,2,4-triazin-5 (2H) -ones |
| 06/22/2006 | DE102004060984A1 New 4-heterocyclyl-benzamide derivatives, useful as antithrombotic agents for treating or preventing e.g. deep vein thrombosis or reocclusion after angioplasty, are inhibitors of factor Xa and other serine proteases |
| 06/22/2006 | DE102004060699A1 Verfahren zur Herstellung von Candesartan Process for the preparation of candesartan |
| 06/22/2006 | CA2592353A1 Tetrahydroisoquinoline compounds for treatment of cns disorders |
| 06/22/2006 | CA2591724A1 2-(phenyl or heterocyclic)-1h-phenantrho[9,10-d]imidazoles as mpges-1 inhibitors |
| 06/22/2006 | CA2591033A1 Heterocyclic aspartyl protease inhibitors |
| 06/22/2006 | CA2590843A1 Novel hydantoin derivatives as metalloproteinase inhibitors |
| 06/22/2006 | CA2590687A1 Process for preparing voriconazole |
| 06/22/2006 | CA2589793A1 4-(4-(imidazol-4-yl)pyrimidin-2-ylamino) benzamides as cdk inhibitors |
| 06/22/2006 | CA2589501A1 Indolinones and their use as antiproliferative agents |
| 06/22/2006 | CA2588909A1 Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor and uses thereof |
| 06/22/2006 | CA2588384A1 Tetrahydrocarbazoles as active agents for inhibiting vegf production by translational control |
| 06/22/2006 | CA2587501A1 Method for production of candesartan |
| 06/21/2006 | EP1671955A1 Cationic symmetric imidazole diazocompounds with a non cationic linking group, compositions comprising them, dying process and kit thereof |
| 06/21/2006 | EP1671949A2 Substituted phenylamines and pyridinylamines |
| 06/21/2006 | EP1670794A2 Vanilloid receptor ligands and their use in treatments |
| 06/21/2006 | EP1670790A1 Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof |
| 06/21/2006 | EP1670787A2 Cytokine inhibitors |
| 06/21/2006 | EP1670786A1 Quinazoline derivatives |
| 06/21/2006 | EP1670785A1 Salts and polymorphs of a pyrrole-substituted indolinone compound |
| 06/21/2006 | EP1670784A1 Heteroaryl-substituted imdazole derivatives as glutamate receptor antagonists |
| 06/21/2006 | EP1670774A1 Quinoxaline compounds |
| 06/21/2006 | EP1670771A1 Compounds and compositions as protein kinase inhibitors |
| 06/21/2006 | EP1670768A1 Compounds and methods for treating dyslipidemia |
| 06/21/2006 | EP1670758A1 Substituted indole acid derivatives and their use as pai-1 inhibitors |
| 06/21/2006 | EP1670757A1 Pyrrole and pyrazole derivatives as potentiators of glutamate receptors |
| 06/21/2006 | EP1670739A2 Cyclic diamines and derivatives as factor xa inhibitors |
| 06/21/2006 | EP1670474A2 Cyclic pyrazinoylguanidine sodium channel blockers |
| 06/21/2006 | EP1670460A2 Pyrazole derivatives as cannabinoid receptor modulators |
| 06/21/2006 | EP1670457A1 Bicycl 3.1.1]heptane substituted benzimidazolone and quinazolinone derivatives as agonists on human orl1 receptors |
| 06/21/2006 | EP1268419B1 Pyrrolidine derivatives useful as bax inhibitors |
| 06/21/2006 | EP1255734B1 Isatine derivatives with neurotrophic activity |
| 06/21/2006 | CN1791596A Anti-cancer medicaments |